Forgot your password?
Forgot your username?
ECCO General Assembly
ECCO Governing Board
ECCO Strategic Council
ECCO Operational Board
ECCO & IBD
Congresses & Events
13th Congress of ECCO, Vienna 2018
12th Congress of ECCO, Barcelona 2017
11th Congress of ECCO, Amsterdam 2016
10th Congress of ECCO, Barcelona 2015
9th Congress of ECCO, Copenhagen 2014
8th Congress of ECCO, Vienna 2013
7th Congress of ECCO, Barcelona 2012
6th Congress of ECCO, Dublin 2011
ECCO Educational Workshops
IBD Nurse Education Programme
ECCO: EduCational COurse for Industry
N-ECCO Network Meeting
N-ECCO Research Forum
P-ECCO Educational Course
S-ECCO IBD Masterclass
Y-ECCO Basic Science Workshop
H-ECCO IBD Masterclass
School for Clinical Trialists
Fellowships and grants
ECCO CONFER Cases
Published ECCO Guidelines
ECCO Topical Review
Published ECCO Topical Reviews
ECCO-EFCCA Patient Guidelines
CD Patient Guidelines
UC Patient Guidelines
JCC local editions
10 Year JCC Anniversary
ECCO IBD Mobile App
Press & Awareness
EU Research Projects
FP7 Sadel Project
Horizon 2020 - BIOCYCLE Project
Standards of Care
Poster presentations: Clinical: Therapy & observation (2015)
in the Abstract Database
* = Presenting author
Poster presentations: Clinical: Therapy & observation (2015)
P289 Extracolonic neoplasias in Inflammatory Bowel Disease patients: Data from the GETECCU ENEIDA registry
P289a Intestinal transplantation for Crohns Disease: A 5-year nationwide follow-up
P290 Impact of induction therapy with 3 doses of infliximab on deep remission in paediatric patients with active Crohn's Disease
P291 Association between Inflammatory Bowel Disease activity and therapeutic drug monitoring of azathioprine and infliximab comparing free and total antidrug antibody measurement
P292 Immunogenicity of 13-valent pneumococcal conjugated vaccine in pediatric patients with inflammatory bowel disease
P293 The sooner, the better: Early treatment of Crohn's Disease precludes a bad outcome
P294 Is the tuberculin skin test alone accurate in modeate-to-severe BCG vaccinated patients with Inflammatory Bowel Disease treated with immunosuppressives to test for latent tuberculosis?
P295 Preliminary assessment of efficacy and safety of switching between originator and biosimilar infliximab in paediatric Crohn disease patients.
P296 Isoniazid prophylaxis may not prevent tuberculosis reactivation during anti-TNF treatment
P297 Utility of post-induction trough level measurement in planning infliximab maintenance therapy for pediatric IBD
P298 Validation of the mobile Health Index (mHI) for remote monitoring of IBD disease activity
P299 Ulcerative colitis and paediatric liver transplantation for primary sclerosis cholangitis - multi-case report
P300 Effect of vedolizumab on health-related quality of life (HRQoL) in patients with Crohn's disease
P301 Vedolizumab for induction of remission in Crohn's disease in adults, a systematic review and meta-analysis
P302 Pharmacoszintigraphic investigations of a high-dose mesalazine tablet with a new coating
P303 Real life effectiveness of Adalimumab for the treatment of ulcerative colitis: comparison between anti-TNF-naïve and non-naïve patients. Results from the Spanish ENEIDA Registry.
P304 Crohn Disease localization does not contribute to the course of maintenance therapy with infliximab in children.
P305 Infliximab serum levels do not predict remission after the induction phase in Crohn's Disease patients
P306 Embedding pharmaceutical care into the multidisciplinary team
P307 Clinical outcome of adalimumab therapy in patients with ulcerative colitis previously treated with infliximab: a Danish single center cohort study
P308 Interobserver agreement in assessment of Rutgeerts' score of endoscopic recurrence of ileal Crohn's disease: a substudy of the TOPPIC trial
P309 The effects of preoperative adsorptive leukocytapheresis on inflammatory cytokines and septic complications after restorative proctocolectomy for ulcerative colitis: a prospective randomized study
P310 Systematic review: The financial burden of surgical complications in patients with ulcerative colitis
P311 Measurement of functional blocade of TNF-alpha by anti-TNF agents is a stronger predictor than trough levels and anti-drug antibodies: 2-year prospective clinical data
P312 Evolution of the Lemann index in Crohn's disease: a retrospective study
P313 Medication use and its perception by female inflammatory bowel disease patients.
P314 Biosimilar infliximab in inflammatory bowel diseases: first interim Results from a prospective nationwide observational cohort
P315 Remission induction therapy in patients with remitting-relapsing ulcerative colitis dependent and refractory to corticosteroids or intolerant to thiopurines
P316 Impact of anti-TNF therapy in the number of hospitalizations and surgeries - Overview of clinical practice in a tertiary referral center
P317 Clinical value of routine therapeutic anti-TNF drug monitoring (TDM) in Inflammatory Bowel Disease (IBD) patients in clinical practice
P318 Management of loss of response to infliximab. Results of a descriptive study of a cohort of inflammatory bowel disease patients.
P319 Adalimumab long-term effectiveness in adults with Crohn's Disease: Observational data from the PYRAMID registry
P319a Deep clinical remission in patients with Ulcerative Colitis: Evaluating the effects of vedolizumab on various combinations of endoscopic and patient-reported outcomes
P320 Clinical relevance of faecal calprotectin variability in Inflammatory Bowel Disease
P321 Postoperative complications after ileo-caecal resection for Crohn's Disease: a prospective multicentre study.
P322 Cost per clinical outcomes with biologics for the treatment of moderately to severely active ulcerative colitis
P323 Risk factor analysis for therapy related adverse events and infections in elder patients with Inflammatory Bowel Disease; An analysis from the IG-IBD aged study
P324 Biomarkers predict lack of response to anti-TNF in Moderate to Severe Ulcerative Colitis
P325 Unfavorable initial thiopurine response does not reduce anti-drug antibody formation compared to thiopurine responders in Crohn's disease patients treated by thiopurine & infliximab co-therapy
P326 Three-year steroid free remission and safety of azathioprine treatment in inflammatory bowel disease patients.
P327 Colorectal cancer in IBD patients treated or untreated with anti-TNFs: A retrospective matched-pair study in a 14 years follow up
P328 P-glycoprotein 170 (P-GP) functional activity in peripheral blood lymphocytes (PBL) of IBD patients during treatment with anti-TNFs
P329 Intermittent vancomycin and gentamicin as exclusive therapy for severe very early onset Inflammatory Bowel Disease
P330 Efficacy and safety of vedolizumab with advancing age in patients with Crohn's disease: Results from the GEMINI 2 study
P331 Endoscopic Balloon Dilation Delays the Need for Subsequent Surgery in Patients With Strictures In Crohn's Disease Even In Ileocolonic Anastomotic (ICA) Localization ?
P332 Impact of Inflammatory Bowel Disease on Japanese patients' lives: International comparison of patients' views
P333 Safety of fecal microbiota transplantation in patients with chronic colitis and immunosuppressive treatement.
P334 Level of education and knowledge about female health issues in patients with inflammatory bowel disease.
P335 Screening for enteric infection in inflammatory bowel disease patients contacting the IBD helpline and presenting with disease flares
P336 Intestinal transplantation for Crohn's Disease: The Cambridge experience since 2008
P337 Profile and outcomes of mercaptopurine therapy in inflammatory bowel disease
P338 Serologic profile and reactivation of Hepatitis B in rheumatic and Inflammatory Bowel Disease patients treated with TNF inhibitors bowel disease
P339 High dose intravenous iron isomaltoside 1000 in subjects with inflammatory bowel disease - the PROMISE trial
P340 Adalimumab treatment in Ulcerative Colitis patients who are naïve to anti-TNF: Week 8 of our pilot study
P341 Endoscopy Assessment at 1-year Identifies Long-term Responders to Thiopurines Maintenance Therapy in Patients with Crohn's Disease
P342 Meta-analysis: Does aspirin or non-aspirin non-steroidal anti-inflammatory drug use reduce colorectal cancer risk in patients with inflammatory bowel disease?
P343 Misconceptions about reproductive issues in female patients with inflammatory bowel disease.
P344 Restless-Legs-Syndrome and iron deficiency in patients with inflammatory bowel disease
P345 Rapid weight increase in Infliximab treated Crohn's disease patients is sustained over time
P346 Early treatment with infliximab for Crohn's disease patients
P347 Patient perception towards faecal microbiota transplantation for treatment of Inflammatory Bowel Disease
P348 How could female infertility be reduced after open IPAA
P349 Consensus Statements on the Management of Acute Severe Ulcerative Colitis
P350 Mucosal and histologic response to cyclosporin in ulcerative colitis: a cohort study
P351 Does failure to respond to one anti-TNF agent in Ulcerative Colitis predict treatment failure with other anti-TNF agents?
P352 Unblinded Results from a dose-escalating placebo-controlled study with allogeneic bone marrow-derived mesenchymal stem cells for the treatment of refractory perianal fistulas in patients with Crohn's disease
P353 Are we under-recognizing skewed thiopurine metabolism in IBD patients? Routine thiopurine metabolite measurement yields clinical benefit at 12 months: A retrospective observational study.
P354 Analysis of outcomes after non-medical switching of anti-tumor necrosis factor agents
P355 What is treat-to-target of Crohn's Disease: the comparison of long-term outcome among patients with mucosal healing, deep remission and biological remission ?
P356 Durable Clinical Remission and Response in Adalimumab-Treated Patients with Ulcerative Colitis
P357 Integrated care pathways for Inflammatory Bowel Disease Surgery: Design and first analysis.
P358 Long term efficacy of granulocyte-monocyte-apheresis in ulcerative colitis elderly patients. The Italian Registry of Therapeutic Apheresis.
P359 Meta-analysis of the effects of anti- tumour necrosis factor alpha therapies on pregnancy outcomes in women with Inflammatory Bowel Disease
P360 Adalimumab in perianal Crohn's disease treatment: Experience of a tertiary center
P361 Effects of azathioprine on outcome of pregnancy in Inflammatory Bowel Disease patients: A prospective study
P362 Agalactosyl IgG predicts therapeutic effect of anti-TNF agents in patients with Crohn's Disease
P363 How did changes in medical protocols affect the length of resected ileum in Crohn's disease over the last decade?
P364 Immunization status in IBD patients -a single centre study in Southern Italy
P365 Direct rescue treatment is justified in moderate flares of Ulcerative Colitis worsening with oral corticosteroid therapy
P366 Withdrawing or continuing maintenance treatment with thiopurines in patients with Crohn's Disease in sustained clinical remission: a lifetime risk-benefit analysis
P367 Dietary fiber intake in children with Inflammatory Bowel Disease
P368 Ustekinumab in super-refractory Crohn´s disease patients
P369 Diffusion-Weighted magnetic resonance enterocolonography before treatment predicts remission after anti-TNF therapy in Crohn's disease
P370 IBD-Control Questionnaire: validation and evaluation in clinical practice
P371 Are biologics a safe option for elderly patients with inflammatory bowel disease?
P372 Efficacy and safety of endoscopic balloon dilatation in the Inflammatory Bowel Disease: Results of the ENEIDA database.
P373 Meta-analysis: Does folate supplementation reduce colorectal cancer risk in patients with inflammatory bowel disease?
P374 The clinical usefulness of the web based message system between patients with Crohn’s disease and their physicians
P375 Efficacy of Exclusive Enteral Nutrition (EEN) in Active Crohn’s Disease with Complications or Failure of Medical Treatment
P376 Mucosal healing in IBD: Therapy maintenance or de-escalation therapeutic approach in patients achieving mucosal healing
P377 Assessment of safety and efficacy of ferric carboxymaltose (Ferinject ®) in the management of iron deficiency with anaemia (IDA) or without anaemia in children and adolescents with inflammatory bowel disease (IBD)
P378 Early hs-CRP normalization and mucosal healing are effective predictors for 1-year mucosal healing
P379 Prolonged and repeated steroid exposure in inflammatory bowel disease: National population based study
P380 Risk Factors for Drug-induced Lupus secondary to Anti-tumor Necrosis Factor Agents used in Inflammatory Bowel Disease: A Multicenter Case-control Study in Madrid
P381 Feasibility and value of stool anti-TNF measurement in IBD patient in loose of response: a preliminary study
P382 Prevalence of impaired muscle strength in an IBD outpatient cohort.
P383 Overweight impairs short-term outcomes of laparoscopic IBD surgery. A comparative analysis of 639 consecutive patients.
P384 Golimumab maintenance treatment and fecal calprotectin predict continuous clinical response in ulcerative colitis.
P385 Azathioprine and 6-Mercaptopurine use in the Swiss IBD cohort: adverse effects, causes of discontinuation and risk of "flares" according to 6-TG levels
P386 Durability of the anti-HBs titers after vaccination against Hepatitis B virus (HBV) in patients with Inflammatory Bowel Disease (IBD)
P387 Disease course and colectomy rate in ulcerative colitis: a follow-up cohort study of a tertiary referral center in Tuscany
P388 Fistula Healing in Perianal Crohn's Disease - With or Without Anti-TNF Therapy?
P389 A double-blind clinical trial on Trichuris suis
P390 Thiopurines are more effective in Crohn's Disease than in Ulcerative Colitis, despite a global high rate of treatment failure: A single centre experience in the use of thiopurines in the era of biologics
P391 Effect of Adalimumab on Clinical Laboratory Parameters in Paediatric Crohn's Disease Patients from IMAgINE 1
P392 Low uptake of cervical screening in immunosuppressed patients with Inflammatory Bowel Disease at a district general hospital
P393 Measles, Mumps and Rubella Seronegativity Rates in IBD Patients Commencing Biologic Therapy
P394 Prevalence of malnutrition in patients with Inflammatory Bowel Disease - a Romanian National Register based study
P395 Therapeutic adherence in patients with inflammatory bowel disease.
P396 Adalimumab induction therapy achieves clinical remission and response in chinese patients with Crohn's Disease
P397 Analysis of Mucosal TNFSF15/TL1A Expression in Korean IBD Patients
P398 An Open-label, Pilot Study to Assess Feasibility and Safety of Fecal Microbiota Transplantation in Patients with Mild-Moderate Ulcerative Colitis: preliminary results.
P399 Short- and long-term outcomes of infliximab treatment for refractory ulcerative colitis and associated prognostic factors: a Japanese single-center study
P400 Setting standards for multi-disciplinary team driven care in inflammatory bowel disease service provision - an expert consensus on key specialists to be involved
P401 Adalimumab as first-line anti-TNF treatment in ulcerative colitis. A "real-life" observational study
P402 Anal neoplasia in inflammatory bowel disease is associated with HPV and perianal disease
P403 Colectomy is not a cure for ulcerative colitis: A systematic review
P404 Calcineurin inhibitors are safe and effective for induction of remission in patients commencing vedolizumab for IBD
P405 Pediatric Crohn's disease with iron deficiency anemia: A follow-up study of intravenous iron treatment
P406 Adipose derived regenerative cells injection as a novel method of enterovesical fistula treatment in Crohn's Disease: A case report
P407 Prevalence of methotrexate intolerance in pediatric inflammatory bowel disease
P408 Differences in biologic efficacy and dose-escalation among anti-TNF agents in Crohn´s disease and ulcerative colitis
P409 Smoking is associated with extra-intestinal manifestations in inflammatory bowel disease
P410 Anti-TNF improves iron availability in Inflammatory Bowel Diseases, modulating Pro-hepcidin in an Erythroferrone-independent fashion
P411 Five year outcomes of Crohn's anastamotic strictures treated with balloon dilatation
P412 Fecal calprotectin as predictor of relapse in asymptomatic Ulcerative Colitis
P413 Healthcare expenditures for inflammatory bowel disease peak in patients with a short disease duration
P414 Cannabidiol for symptomatic treatment of ulcerative colitis: Results from a randomised, double-blind, placebo-controlled, parallel group, multi-centred pilot study
P415 Fecal calprotectin and serum C-reactive protein predict outcome of infliximab induction therapy in inflammatory bowel disease.
P416 Is faecal calprotectin (FC) a reliable marker of isolated small bowel Crohn's disease (CD) activity?
P417 Ileal pouch-anal anastomosis for dysplasia or cancer complicating inflammatory bowel disease: should a total mesorectal excision always be performed? An analysis of 39 consecutive patients.
P418 Looking beyond the mucosa: transmural healing after one-year anti-TNF± therapy in Crohn's disease
P419 Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: Pooled Analysis from ULTRA 1 and ULTRA 2
P420 Thiopurine metabolite testing to guide management in inflammatory bowel disease (IBD) yields clinical benefit at 12 months: A retrospective observational study.
P421 Transitional care in Inflammatory Bowel Disease - a single center experience
P422 'IBDPassport': Evaluating the quality of an internet-based travel resource for Inflammatory Bowel Disease
P423 Evaluation and long-term benefit of mucosal healing in Crohn's disease patients treated with infliximab
P424 Th1 and Th17 response in relation with steroid response in Crohn's disease
P425 Endothelial function and cardiovascular risk in Inflammatory Bowel Disease in remission phase
P426 Disease phenotype, activity, and clinical course based on the C-reactive protein level at diagnosis in Crohn's Disease: results from the CONNECT study
P427 Fecal microbiota transplantation in refractory pediatric UC - preliminary data.
P428 Rescue therapy with anti-TNF therapy in patients with Crohn's Disease and post-operative recurrence with intolerance or failure of thiopurines
P429 Influence of Disease Course on Therapeutic Effect of IFX in Crohn's disease
P430 Assessment of safety and efficacy of biosimilar infliximab in children with Crohn disease: a preliminary report.
P431 Serology panel for prediction relapse after discontinuation of infliximab in patients with Crohn's disease achieving clinical remission
P432 Do tumor necrosis factor alpha antagonists reduce the development of advanced colonic neoplasia?
P433 Efficacy of vedolizumab with concomitant corticosteroid or immunomodulator use in patients with ulcerative colitis from GEMINI 1
P434 Clinical utility of routine measurement of Anti-TNF levels and their antibodies in inflammatory bowel disease (IBD)
P435 Maintenance of Remission with Partial Enteral Nutrition Therapy in pediatric Crohn's Disease: A retrospective study.
P436 Efficacy and safety of azathioprine treatment in Asian patients with Ulcerative Colitis
P437 Short term prevalence of nodular regenerative hyperplasia of the liver in IBD patients treated with allopurinol-thiopurine combination therapy
P438 Prospective, randomized clinical trial comparing the efficacy of two vaccines against hepatitis B virus (HBV) in inflammatory bowel disease (IBD) patients
P439 Deep remission as a predictor of clinical outcomes in vedolizumab-treated patients with ulcerative colitis
P440 Curcumin add-on therapy for induction of remission in mild-moderate active Ulcerative Colitis: A multi-center, prospective, randomized, double-blind, placebo-controlled trial
P441 Infliximab-Related Infusion Reactions: Systematic Review of Preventive and Management Practices
P442 Outcome of early surgery versus aggresive medical therapy in patients with newly diagnosed limited inflammatory/obstructive (A2/3L1B1/2) terminal Ileitis: A two-year, prospective, single-center, pilot study
P443 Soluble TNF serum levels during the induction phase in Crohn's Disease patients with anti-TNF treatment
P444 Successful allogeneic haematopoietic stem cell transplantation (HSCT) for refractory Paediatric Crohn's Disease without an identifiable genetic mutation - A case report
P445 Significance of non-alchoholic fatty liver disease in patients with Crohn's disease.
P447 Early initiation of adalimumab significantly diminishes post-operative Crohn's Disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial
P448 How good are we at detecting and managing folate deficiency in inflammatory bowel disease?
P449 Anti-drug Antibodies Inhibit Neutralization of TNF-alpha in Infliximab Treated Patients with Inflammatory Bowel Disease (IBD)
P450 Poor recognition and management of iron deficiency anaemia in inflammatory bowel disease: a missed opportunity
P451 Cost of hospitalisations among moderate-to-severe Ulcerative Colitis patients treated with adalimumab and conventional non-biologic therapies
P452 Usability study of a smartphone-based patient monitoring system measuring Calprotectin for therapy follow-up
P453 Infliximab population pharmacokinetic modelling in patients with Inflammatory Bowel Disease (IBD): Patient factors influencing infliximab pharmacokinetics
P454 A protocol to avoid corticosteroids in Crohn's disease requiring luminal surgery
P455 Need and predictors of colectomy for Ulcerative Colitis patients in the biologic therapy era. A real life experience in a tertiary referral center
P456 First observations of the use of biosimilar infliximab for treatment of ulcerative colitis in paediatric population.
P457 Anti-TNF therapy successfully improves anemia in Inflammatory Bowel Disease - Results from a tertiary referral center
P458 Cutaneous events during anti-tumour necrosis factor (anti-TNF) treatment at a London Inflammatory Bowel Disease (IBD) centre
P459 Characteristics of Pediatric Crohn's Disease in a Tertiary Center in China according to Paris Classification
P460 Efficacy and Safety of Granulocyte/Monocyte Apheresis in Active Ulcerative Colitis Using an Adsorber Device Based on Cellulosic Filaments
P461 Therapeutic requirements and health resources in the treatment of clinically active ulcerative proctitis
P462 A single factor of compliance may not be sufficient to improve outcomes in Ulcerative Colitis
P463 Achieving Remission in Paediatric Inflammatory Bowel Disease (pIBD): Data on Mono- vs. Combination Therapy using the ImproveCareNow (ICN) Data Base
P464 Short- and Long-term Outcomes of Acute Severe Ulcerative Colitis in Korea: The 1999-2005 cohort
P465 Inadequate immunisation against viral hepatitis B and no detected cases of hepatits C infection among patients with Inflammatory Bowel Disease
P466 Not all penetrating events are the same: differences and similarities in patients with or without entero-urinary fistulas.
P467 Systematic Review and Meta-Analysis: Infliximab or Ciclosporin as Rescue Therapy in Patients with Severe Ulcerative Colitis Refractory to Steroids
P468 Appendectomy is associated with an increased risk of colonic neoplasia in Ulcerative Colitis
P469 Accelerated treatment strategy in Inflammatory Bowel Diseases: Is it associated with a change in the disease course?
P470 Changes in serum through levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease
P471 Infliximab trough levels are lower in patients with acute severe, compared to moderate-severe ulcerative colitis patients
P472 Risk of relapse after anti-TNF discontinuation in Inflammatory Bowel Disease: A meta-analysis
P473 Antibodies to infliximab, body weight and low serum albumin levels increase clearance of infliximab, a population pharmacokinetic study in 324 IBD patients
P474 Anti-TNFα treatment efficacy in prevention of postoperative recurrence in Crohn's disease depends on previous exposure to anti-TNFα agents
P475 What is our success on complex perianal fistulae healing under optimal medical treatment ending up with ileostomy?
P476 EArly SurgerY or Immunosuppression - EASY study
P477 Biological Therapy Is Able To Modify The Disease Progression of Crohn's Disease Preventing Its Long-Term Associated Disability - A Study Performed By Using The Lèmann Score
P478 Vitamin D status and response to anti-tumor necrosis factor-alpha therapy in inflammatory bowel disease
P479 Factors Associated with Development of Endoscopic Stricture in Patients with Crohn's Disease Treated with Infliximab
P480 Efficacy of switching to pH-dependent release formulation of mesalazine at 3.6 g/day from time-dependent release formulation of mesalazine at 4.0 g/day in patients with Ulcerative Colitis
P481 A Scandinavian prospective observational study of iron isomaltoside 1000 treatment: Clinical practice and outcomes in iron deficiency anaemia in patients with IBD
P482 Infliximab population pharmacokinetic modelling in patients with Inflammatory Bowel Disease: estimation of individual pharmacokinetic parameters and trough levels prediction
P483 ABO blood group in monitoring response to infliximab treatment for Crohn's Disease
P484 Is topical therapy necessary for patients with acute mild and/or moderately active extensive or left-sided Ulcerative Colitis treated with mmx-mesalazine? A pilot, single-center, faecal calprotectin-guided study
P485 Pregnancy and its outcomes in female IBD patients.
P486 Assay of infliximab trough levels and of total antibodies to infliximab in the management of loss of response
P487 A Study of Optimal Screening for Latent Tuberculosis in Patients with Inflammatory Bowel Disease
P488 Virus associated hemophagocytic syndrome: rare but serious complication of azathioprine treatment in patients with Crohn´ s disease
P489 Faecal microbiota transplantation via nasogastric route for the treatment of recurrent and antibiotic refractory Clostridum Difficile infection: The UK experience
P490 Comparative analysis of the cost of maintenance treatment of Ulcerative Colitis with different compound preparation of mesalazine
P491 "Now I know I'm not alone": Participating in a disease-specific summer camp improves the quality of life of young people with Inflammatory Bowel Disease
P492 Resolution of factor XI (FXI) deficiency in refractory Ulcerative Colitis (UC) after surgery: A case report
P493 Adding 5-Aminosalicylate to Immunomodulators Showed No Additional Benefit in Crohn's Disease
P494 Exploring the efficacy of weight-based dosing of thiopurine therapy in relation to metabolite levels at week 12 in patients with Inflammatory Bowel Disease
P495 Azathioprine versus mycophenolate mofetil in combination with anti-TNF alpha agents in the management of Crohn's disease
P496 Prevalence and reasons for drug non-adherence in a European cohort of ulcerative colitis patients: The UCandME survey
P497 Surgery and hospitalization in inflammatory bowel disease - what has changed in the last 25 years? - Overview of clinical practice in a tertiary referral center
P498 Final Results of SOLE study: Focus on patient adherence/satisfaction and their correlation with patient worries
P499 Individualized therapy is long-term cost-effective compared to dose intensification in Crohn's disease patients failing infliximab
P500 Evolution after anti-TNF drug discontinuation in patients with inflammatory bowel disease (IBD): a multicenter long-term follow-up study.
P501 Relationship between measures of infliximab exposure and clinical outcome of infliximab intensification at therapeutic failure in Crohn's disease
P502 Predictors of bad response to infliximab in Ulcerative Colitis patients (ECIA study. ACAD)
P503 Infliximab and adalimumab serum levels predict probability of mucosal healing
P504 Clinical outcomes associated with switching or discontinuation of anti-TNF inhibitors for non-medical reasons
P505 Biosimilar but not the same
P506 Predictors of Health-related Quality of Life in Asian Patients with Inflammatory Bowel Disease: Psychological, Clinical and Demographic factors
P507 Long term outcome of children born to IBD mothers: preliminary result from a multicenter retrospective study in the Netherlands
P508 Vedolizumab for the Treatment of Fistulising Crohn's Disease: An Exploratory Analysis of Data From GEMINI 2
P509 Risk score for Crohn's Disease activity using red cell distribution width, platelet count, erythrocyte sedimentation rate and C-reactive protein
P510 Efﬁcacy and safety of certolizumab pegol in an unselected Crohn's disease population: long-term data of the FACTS III survey
P511 Efficacy and safety of granulocyte/monocyte adsorptive apheresis in steroid-dependent Active Ulcerative Colitis with insufficient response or intolerance to immunosuppressants and/or biological therapies (the ART trial): Results at 24 and 48 weeks
P512 Bowel ultrasound is useful in Crohn's disease monitoring: Analysis from the TRUST study in Germany
P513 The effect of intravenous iron treament on quality of life in Inflammatory Bowel Disease patients with non-anemic iron deficiency
P514 Need for anti-TNF escalation in Inflammatory Bowel Disease - A single center experience
P515 Basic laboratory parameters of inflammation compared to serum hepcidin level in inflammatory bowel disease (IBD)
P516 Immunisation status and factors influencing vaccination decision-making in patients with inflammatory bowel disease
P517 Efficacy of antisecretory factor in reducing high intestinal output in patients with ileostomy for Crohn's disease
P518 Five year outcomes of Crohn's small bowel strictures treated with double balloon enteroscopic dilatation.
P519 Thiopurines Undertreatment among Inflammatory Bowel Disease Patients Referred for antiTNF Therapy
P520 Accuracy of rapid fecal calprotectin test in monitoring Inflammatory Bowel Diseases under treatment with TNF-alpha antagonists
P521 Correcting iron deficiency anaemia in IBD with oral ferric maltol: Use of proton pump inhibitors does not affect efficacy
P522 Factors reducing bone mineral density in patients with inflammatory bowel disease
P523 Efficacy of cyclosporine therapy in intestinal Behçet's disease
P524 Could histological lesions predict reactivation in ulcerative colitis patients with mucosal healing?
P525 Evolution of IBD-related costs over two years of follow up: increase of anti-TNF ± therapy related costs with a decline of hospitalization costs
P526 Impact of postinduction infliximab trough level and disease activity on primary response in Crohn's Disease
P527 Characterization of variables determining satisfaction with life in Crohn's Disease patients
P528 Efficacy of vedolizumab with concomitant corticosteroid or immunomodulator use in patients with Crohn's disease in GEMINI 2
P529 Maintenance of clinical remission in Crohn's disease patients after discontinuation of antiTNF agents: Results from a single centre cohort
P530 Is microscopic colitis a rare disease in Southern Europe? A prevalence population-based study in Terrassa (Spain)
P531 Intravenous corticosteroid dosing in paediatric acute severe Ulcerative Colitis (ASC): A multicenter propensity score study
P532 Quality of Care in Family Planning and Pregnancy - an Online Survey among 475 Female Patients with Inflammatory Bowel Disease
P533 Assessment of disease-related therapeutic protein drug-drug interaction (TP-DDI) for etrolizumab in patients with moderately to severely active ulcerative colitis (UC)
P534 Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: a randomized, double-blinded, placebo-controlled multicenter trial
P535 Transition in adolescents with IBD: study of a measuring instrument for transfer readiness
P536 Long term efficacy and safety for Sequential Rescue Treatments in patents with steroid refractory Ulcerative Colitis - Two years follow up data
P537 The effect of anti TNF induction therapy on body composition parameters in inflammatory bowel disease